Most clinical monoclonal antibody drugs that rely on direct effector-cell activity are known to target antigen receptors that are buried deep inside the glycocalyx, often within 10 nm from the membrane surface 13,14 , suggesting that their effectiveness may be highly dependent upon crowding near the receptor
Though less popular than the newer weekly injections like semaglutide and tirzepatide , it still represented a meaningful cost line
The fundamental concern with stacking multiple GLP-1 agonists is receptor saturationonce the GLP-1R receptor is fully occupied by one compound, adding another does not improve outcomes
he consults for Eisai, Lilly, NeuroTherapia, Signant Health, Novo Nordisk, Anavex Life Sciences, Alzheon, Cognito Therapeutics, GSK and AbbVie
With the patent expiry, the market is opening up like never before
What are the benefits of Glutathione: Reduces oxidative stress